Literature DB >> 33444893

Excellent performance of CHROMagarTM LIN-R to selectively screen for linezolid-resistant enterococci and staphylococci.

Franziska Layer1, Robert E Weber1, Carola Fleige1, Birgit Strommenger1, Christiane Cuny1, Guido Werner2.   

Abstract

The increasing number of nosocomial pathogens with resistances against last resort antibiotics like linezolid leads to a pressing need for the reliable detection of these drug-resistant bacteria. National guidelines on infection prevention, e.g., in Germany, have already recommend screening for linezolid-resistant bacteria, although a corresponding screening agar medium has not been provided. In this study we analyzed the performance and reliability of a commercial, chromogenic linezolid screening agar. The medium was capable to predict more than a hundred linezolid-resistant isolates of E. faecium, E. faecalis, S. aureus, S. epidermidis, and S. hominis with excellent sensitivity and specificity. All isolates were collected at the National Reference Centre between 2010 and 2020.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enterococcus; Staphylococcus; cfr; optrA; poxtA

Year:  2020        PMID: 33444893     DOI: 10.1016/j.diagmicrobio.2020.115301

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  2 in total

1.  Prevalence of linezolid-resistant organisms among patients admitted to a tertiary hospital for critical care or dialysis.

Authors:  Kornelia Maria Dembicka; James Powell; Nuala H O'Connell; Noreen Hennessy; Grainne Brennan; Colum P Dunne
Journal:  Ir J Med Sci       Date:  2021-09-10       Impact factor: 2.089

2.  Evaluation of CHROMagar™ LIN-R for the Screening of Linezolid Resistant Staphylococci from Positive Blood Cultures and Nasal Swab Screening Samples.

Authors:  Delphine Girlich; Liliana Mihaila; Vincent Cattoir; Frédéric Laurent; Christine Begasse; Florence David; Carole-Ann Metro; Laurent Dortet
Journal:  Antibiotics (Basel)       Date:  2022-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.